Concepedia

P.A. Ott

PO

Statistics

Publications

4

Citations

219

H-Index

4

Active since

2015

Affiliations

Princess Margaret Cancer Centre(Current)

Institut Gustave Roussy

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

P.A. Ott is an author at Princess Margaret Cancer Centre specializing in cancer therapeutics, radiation oncology, and medicine.

Top concepts

Publications per year

2015–2017

4

Publications

4

Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

HS Rugo, J.P. Delord, S-A. Im et al. · Cancer Research · 2016 · 97 citations

, , +18

Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

Janice M. Mehnert, Hope S. Rugo, Bert H. O’Neil et al. · Annals of Oncology · 2017 · 57 citations · Full text

, , +9

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

Aaron R. Hansen, Christophe Massard, P.A. Ott et al. · Annals of Oncology · 2016 · 48 citations · Full text

, , +7

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

P.A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster et al. · European Journal of Cancer · 2015 · 17 citations

, , +7

Rows per page

1–4 of 4